Alpelisib

Drug Profile

Alpelisib

Alternative Names: BYL-719; NVP-BYL-719

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan-Kettering Cancer Center; Northwestern University; Novartis; Novartis Oncology; Peter MacCallum Cancer Centre; University Health Network
  • Class Amides; Antineoplastics; Dicarboxylic acids; Fluorine compounds; Pyridines; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Multiple myeloma
  • Discontinued Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Uveal melanoma

Most Recent Events

  • 25 Apr 2017 Lawson Health Research Institute plans a clinical trial for Head and neck squamous cell carcinoma (PO) (NCT03138070)
  • 30 Mar 2017 Novartis intends to submit NDA to the US FDA for Breast cancer in 2019
  • 21 Feb 2017 Novartis plans a phase II trial for Breast cancer (NCT03056755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top